ALK
7 drugsAnaplastic Lymphoma Kinase
Predictive biomarker for patient selection in 5 indications
Understanding ALK
What it means: ALK rearrangements create fusion proteins that drive cancer growth. Most common is EML4-ALK fusion in lung cancer.
Why it matters: ALK+ cancers respond to ALK inhibitors: crizotinib, alectinib, brigatinib, lorlatinib. Often occurs in younger, non-smokers.
Testing: Tested via FISH, IHC, or NGS. FISH is the gold standard; NGS can identify specific fusion partners.
7
Approved Drugs
5
Indications
6
Companies
ALK is a precision-medicine biomarker linked to 7 FDA-approved targeted drugs from 6 companies, spanning 5 indications including ROS1-positive metastatic non-small cell lung cancer (NSCLC) in adults, NTRK gene fusion-positive solid tumors in adult and pediatric patients older than 1 month, Non-Small Cell Lung Cancer. Explore the targeted therapies, indications, testing methods, and companies developing ALK drugs below.
Search ALK Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting ALK
ALK Indications
ROS1-positive metastatic non-small cell lung cancer (NSCLC) in adults NTRK gene fusion-positive solid tumors in adult and pediatric patients older than 1 month Non-Small Cell Lung Cancer Anaplastic Large Cell Lymphoma Inflammatory Myofibroblastic Tumor